Consistently, immunohistochemical analysis of patient specimens showed that prostate cancer samples express higher levels of VEGF-A, VEGFR-1, and VEGFR-2 than benign prostatic hyperplasia (BPH) and high-grade prostate intraepithelial neoplasia (HGPIN) samples. This evidence concerns the gene FLT1 and prostate carcinoma.